{"id":2137,"date":"2026-06-03T13:30:23","date_gmt":"2026-06-03T13:30:23","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/06\/03\/cmsc-2026-kesimpta-outperforms-aubagio-in-highly-active-relapsing-ms\/"},"modified":"2026-06-03T13:30:23","modified_gmt":"2026-06-03T13:30:23","slug":"cmsc-2026-kesimpta-outperforms-aubagio-in-highly-active-relapsing-ms","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/06\/03\/cmsc-2026-kesimpta-outperforms-aubagio-in-highly-active-relapsing-ms\/","title":{"rendered":"CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/06\/03\/cmsc-2026-kesimpta-tops-aubagio-highly-active-relapsing-ms\/\" title=\"CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"450\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2026\/05\/iStock-2247055301-800x450.jpg\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"A hand holding a blue marker is seen next to a stethoscope and a stack of small Sticky Note pads, with the words &quot;clinical trials&quot; written on the top sheet in blue.\" style=\"display: block;margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"162744\" \/><\/a><\/p>\n<p>Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely to achieve a composite outcome characterized by an absence of [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/06\/03\/cmsc-2026-kesimpta-tops-aubagio-highly-active-relapsing-ms\/\">CMSC 2026: Kesimpta outperforms Aubagio in highly active relapsing MS<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2026\/06\/03\/cmsc-2026-kesimpta-tops-aubagio-highly-active-relapsing-ms\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely&hellip;<\/p>\n","protected":false},"author":0,"featured_media":2138,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-2137","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=2137"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/2137\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/2138"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=2137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=2137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=2137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}